Table 2—

Clinical and epidemiological features of cases enrolled in the studies reviewed

First author [Ref.]Previously treatedPrevious treatment >1 monthDrugs usedCohort prevalence of HIVLinezolidDefinitions#
MDRXDRMDRXDRMDRXDRMDRXDR
Gandhi 921 (45)44 (100)WHO
Migliori 1074 (58.7)11 (100)235.3+5.5+10 (9.2)0 (0)WHO
Migliori 11178 (49.3)48 (75)2.135617 (5)2 (3.2)WHO/Laserson
Kim 12103 (61.3)24 (55.8)670 (0)0 (0)YesLaserson
Mitnick 1647 (97.9)602 (99.8)3.2+4.2+5.39 (1.5)0 (0)Laserson
Chan 17
Keshavjee 19574 (95.5)29 (100)235 (0.9)0 (0)Laserson
Eker 1894 (53)6 (86)22.44+5+7 (4.9)0 (0)YesLaserson
Kwon 20113 (88)24 (89)660 (0)0 (0)Laserson
Lai 21Microbiological testing
Banerjee 22WHO
Bonilla 2388.9§88.5§1.62Laserson
Kim 241286 (96)73 (97)550 (0)1 (1.7)WHO
  • Data are presented as n or n (%), unless otherwise stated. MDR: multidrug-resistant; XDR: extensively drug-resistant; WHO: World Health Organization. #: according to Laserson et al. 28 and/or the WHO; : median; +: mean; §: data presented as %.